Supplementary Table S2 : Descriptive Characteristic of Adult Subjects

Supplementary Table S2: Descriptive characteristic of adult subjects

Trait / T2D patients / Non-diabetic subjects / Normal-weight non-diabetic subjects / Overweight/obese non-diabetic subjects / Obese non-diabetic subjects
N (M/F) / 2049 (1202/847) / 2028 (1111/917) / 720 (447/273) / 1308 (644/664) / 937 (428/509)
Age (years) / 54.57 (10.50) / 53.65 (10.60) / 53.86 (11.14) / 53.35 (10.23) / 53.46 (10.10)
Weight (Kg) / 67.56 (11.71) / 63.69 (13.16) / 51.86 (7.97) / 70.25 (10.65) / 73.09 (10.53)
Height (m) / 1.62 (0.09) / 1.60 (0.09) / 1.60 (0.09) / 1.60 (0.09) / 1.59 (0.09)
BMI (kg/m2) / 25.91 (4.43) / 24.92 (4.89) / 20.07 (2.11) / 27.58 (3.63) / 28.95 (3.38)
WC (cm) / 92.99 (11.14) / 89.00 (11.67) / 79.30 (7.95) / 94.27 (9.25) / 96.30 (9.26)
WHR / 0.98 (0.07) / 0.92 (0.08) / 0.90 (0.07) / 0.93 (0.08) / 0.93 (0.09)
Total Cholesterol (mmol/l) / 4.56 (1.19) / 4.71 (1.07) / 4.50 (1.06) / 4.82 (1.03) / 4.84 (1.01)
HDL-C (mmol/l) / 1.14 (0.31) / 1.20 (0.33) / 1.21 (0.35) / 1.19 (0.30) / 1.20 (0.30)
LDL-C (mmol/l) / 2.76 (0.96) / 2.98 (0.84) / 2.85 (0.84) / 3.05 (0.80) / 3.05 (0.78)
Triglycerides (mmol/l) / 1.77 (1.16) / 1.43 (0.75) / 1.25 (0.63) / 1.52 (0.75) / 1.55 (0.78)
FPG (mmol/l) / 8.72 (3.54) / 4.80 (0.63) / 4.76 (0.59) / 4.83 (0.63) / 4.86 (0.63)
HbA1c (%) / 8.24 (2.13) / 5.29 (0.52) / 5.18 (0.50) / 5.35 (0.47) / 5.39 (0.46)
FPI (pmol/l) / - / 48.19 (40.01) / 33.81 (37.64) / 55.99 (39.20) / 61.02 (39.96)
HOMA-IR / - / 1.75 (1.53) / 1.22 (1.44) / 2.03 (1.51) / 2.22 (1.53)

Data are presented as mean (standard deviation). Non-diabetic subjects were divided into normal weight (BMI<23Kg/m2), overweight/obese (BMI≥23Kg/m2) and obese (BMI ≥25Kg/m2) categories based on BMI cutoff specific for Asian Indians (Lancet 2004;363:157-163). N: Number of subjects; M: males; F: females; WC: waist circumference; WHR: waist-hip ratio; HDL-C: high density lipoprotein-cholesterol; LDL-C: low density lipoprotein-cholesterol; FPG: fasting plasma glucose; FPI: fasting plasma insulin; HOMA-IR: homeostasis model assessment of insulin resistance.